Nanotechnology for Neurological Disorders: Application of Nanotechnology in Diagnosing and Treating Neurodegenerative Diseases
DOI:
https://doi.org/10.47611/jsrhs.v13i2.6775Keywords:
Nanotechnology, Biomarkers, Parkinson’s, Alzheimer’s, Blood-Brain Barrier, Nanoparticles, NeurodegenerativeAbstract
Nanotechnology is applied for diagnosing and treating neurodegenerative diseases such as Parkinson’s and Alzheimer’s presents riveting opportunities. Targeted drug delivery systems that can cross the blood-brain barrier also known as the BBB can be developed, and there can be particular biomarkers that help in enabling early diagnosis and monitoring of diseases. Additionally, nanotechnology offers potential solutions for improving the delivery of therapeutics to the brain for Alzheimer's disease. The impact of Parkinson's and Alzheimer's diseases worldwide, the current issues in treating these diseases, and how nanotechnology can help develop innovative treatments targeting the underlying mechanisms of these diseases for more effective interventions in the future. Nanotechnology uses nanoparticles which are being used increasingly in various medical fields, including drug delivery, and disease diagnosis. The use of nanoparticles in medicine has shown great promise in the treatment of multiple diseases, specifically neurodegenerative disorders, such as Alzheimer's and Parkinson's disease. The unique properties of nanoparticles are their small size but large surface area, making them ideal for targeted drug delivery.
Downloads
References or Bibliography
Alzheimer’s Disease Facts and Figures. (2023). Alzheimer’s Disease and Dementia. https://www.alz.org/alzheimers-dementia/facts-figures#:~:text=The%20costs%20of%20health%20care
---. “Hybrid Mesoporous Nanoparticles with Highly Integrated Polydopamine for PH-Responsive Membrane Permeation and Drug Delivery.” Colloid and Interface Science Communications, vol. 41, 1 Mar. 2021, p. 100385, www.sciencedirect.com/science/article/abs/pii/S221503822100025X, https://doi.org/10.1016/j.colcom.2021.100385. Accessed 22 Feb. 2024.
Nandi, A., Counts, N., Chen, S., Seligman, B., Tortorice, D., Vigo, D., & Bloom, D. E. (2022). Global and regional projections of the economic burden of Alzheimer’s disease and related dementias from 2019 to 2050: A value of statistical life approach. EClinicalMedicine, 51, 101580. https://doi.org/10.1016/j.eclinm.2022.101580
National Institute on Aging. (2022, October 18). What Are the Signs of Alzheimer’s Disease? National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-symptoms-and-diagnosis/what-are-signs-alzheimers-disease
Ngowi, E. E., Wang, Z., Qian, L., Saleheldin Hassan Helmy, Y. A., Anyomi, B., Li, T., Zheng, M., Jiang, S., Duan, F., Wei, S., Wu, D., & Ji, Y. (2021). The Application of Nanotechnology for the Diagnosis and Treatment of Brain Diseases and Disorders. Frontiers in Bioengineering and Biotechnology, 9. https://doi.org/10.3389/fbioe.2021.629832
Statistics | Parkinson’s Foundation. (n.d.). Www.parkinson.org. Retrieved December 24, 2023, from https://www.parkinson.org/understanding-parkinsons/statistics#:~:text=The%20combined%20direct%20and%20indirect
The Alzheimer’s Disease Crisis – By the Numbers. (n.d.). UsAgainstAlzheimer’s. https://www.usagainstalzheimers.org/learn/alzheimers-crisis#:~:text=Alzheimer%27s%20disease%20and%20related%20dementias
World Health Organization. (2022, June 14). Launch of WHO’s Parkinson disease technical brief. Www.who.int. https://www.who.int/news/item/14-06-2022-launch-of-who-s-parkinson-disease-technical-brief#:~:text=Globally%2C%20the%20prevalence%20of%20Parkinson
World Health Organization. (2022, June 14). Launch of WHO’s Parkinson disease technical brief. Www.who.int. https://www.who.int/news/item/14-06-2022-launch-of-who-s-parkinson-disease-technical-brief#:~:text=Globally%2C%20the%20prevalence%20of%20Parkinson
Published
How to Cite
Issue
Section
Copyright (c) 2024 Aveena Haswani; Virgel Torremocha, Kristina lilova
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
